Madrigal Pharmaceuticals Inc
NASDAQ:MDGL

Watchlist Manager
Madrigal Pharmaceuticals Inc Logo
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Watchlist
Price: 336.74 USD -2.44% Market Closed
Market Cap: 7.3B USD
Have any thoughts about
Madrigal Pharmaceuticals Inc?
Write Note

Gross Margin
Madrigal Pharmaceuticals Inc

96.4%
Current
15%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
96.4%
=
Gross Profit
74m
/
Revenue
76.8m

Gross Margin Across Competitors

Country US
Market Cap 7B USD
Gross Margin
96%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 320.1B USD
Gross Margin
67%
Country US
Market Cap 147.4B USD
Gross Margin
60%
Country US
Market Cap 119.4B USD
Gross Margin
86%
Country US
Market Cap 113.8B USD
Gross Margin
78%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.4B AUD
Gross Margin
52%
Country US
Market Cap 82.6B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 34.3B EUR
Gross Margin
89%
No Stocks Found

Madrigal Pharmaceuticals Inc
Glance View

Market Cap
7B USD
Industry
Biotechnology

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in Conshohocken, Pennsylvania and currently employs 71 full-time employees. The company went IPO on 2007-02-06. The firm is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The firm's product candidate, resmetirom, is a liver-directed, selective thyroid hormone receptor-ß (THR-ß) agonist developed as a once-daily oral pill to treat a number of disease states, including non-alcoholic steatohepatitis (NASH). NASH is a liver disease that affects people with metabolic diseases, such as obesity and diabetes and non-alcoholic fatty liver disease (NAFLD).

MDGL Intrinsic Value
247.45 USD
Overvaluation 27%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
96.4%
=
Gross Profit
74m
/
Revenue
76.8m
What is the Gross Margin of Madrigal Pharmaceuticals Inc?

Based on Madrigal Pharmaceuticals Inc's most recent financial statements, the company has Gross Margin of 96.4%.